$459 Million is the total value of Michael & Susan Dell Foundation's 4 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF TRtr unit | $306,398,000 | +19.6% | 993,637 | 0.0% | 66.71% | +0.5% | |
| VEA | VANGUARD TAX-MANAGED FDSftse dev mkt etf | $94,750,000 | +16.3% | 2,442,641 | 0.0% | 20.63% | -2.2% | |
| VWO | VANGUARD INTL EQUITY INDEX Fftse emr mkt etf | $47,242,000 | +18.1% | 1,192,675 | 0.0% | 10.29% | -0.8% | |
| NGHC | NATIONAL GEN HLDGS CORP | $10,882,000 | +30.6% | 503,571 | 0.0% | 2.37% | +9.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JPMORGAN CHASE & CO | 23 | Q3 2019 | 57.9% |
| AETNA INC NEW | 20 | Q3 2018 | 28.3% |
| INTREXON CORP | 18 | Q2 2018 | 14.6% |
| VANGUARD TAX-MANAGED INTL FD | 15 | Q3 2023 | 100.0% |
| BERKSHIRE HATHAWAY INC DEL | 14 | Q3 2019 | 13.8% |
| ZIOPHARM ONCOLOGY INC | 13 | Q2 2018 | 0.6% |
| CROWN CASTLE INTL CORP NEW | 12 | Q3 2017 | 43.9% |
| MULTIPLAN CORPORATION | 12 | Q3 2023 | 0.3% |
| MULTIPLAN CORPORATION | 8 | Q3 2022 | 26.3% |
| TIME WARNER INC | 8 | Q3 2015 | 17.6% |
View Michael & Susan Dell Foundation's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-04-08 |
| 144 | 2024-03-21 |
| 13F-HR | 2024-02-14 |
| 144 | 2023-12-27 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Michael & Susan Dell Foundation's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.